Trial Profile
A Phase II Study of Durvalumab (MEDI4736) Plus Tremelimumab for the Treatment of Patients With Progressive, Refractory Advanced Thyroid Carcinoma - The DUTHY Trial
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 17 Nov 2023
Price :
$35
*
At a glance
- Drugs Durvalumab (Primary) ; Tremelimumab (Primary)
- Indications Carcinoma; Thyroid cancer
- Focus Therapeutic Use
- Acronyms DUTHY
- 10 Nov 2023 Planned End Date changed from 1 Dec 2023 to 1 Dec 2024.
- 10 Nov 2023 Planned primary completion date changed from 1 Jul 2023 to 1 Jul 2024.
- 10 Nov 2023 Status changed from recruiting to active, no longer recruiting.